Eva Fernandez-Diaz1, Jose A Perez-Vicente2, Ramon Villaverde-Gonzalez3, Leticia Berenguer-Ruiz4, Antonio Candeliere Merlicco5, Maria Luisa Martinez-Navarro6, Julia Gracia Gil1, Carlos M Romero-Sanchez1, Arantxa Alfaro-Saez7,8, Inmaculada Diaz2, Juana Gimenez-Martinez9, Maria Angeles Mendez-Miralles10,11, Jorge Millan-Pascual2, Javier Jimenez-Pancho7, Santiago Mola7, Angel P Sempere9,12,13. 1. Neurology Department, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. 2. Neurology Department, Hospital Universitario Santa Lucía, Cartagena, Spain. 3. Section of Neurology, Hospital Morales y Meseguer, Murcia, Spain. 4. Section of Neurology, Hospital Marina Baixa, La Vila-Joiosa, Spain. 5. Section of Neurology, Hospital Rafael Méndez, Lorca, Spain. 6. Section of Neurology, Hospital Reina Sofia, Murcia, Spain. 7. Section of Neurology, Hospital Vega Baja, Orihuela, Spain. 8. Center for Biomedical Research in the Network in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Elche, Spain. 9. Hospital General Universitario de Alicante, Alicante, Spain. 10. Section of Neurology, Hospital Universitario Los Arcos del Mar Menor, Murcia, Spain. 11. Universidad Católica de Murcia (UCAM), Murcia, Spain. 12. Department of Clinical Medicine, Miguel Hernández University, San Juan de Alicante, Spain. 13. ISABIAL, Alicante, Spain.
Abstract
OBJECTIVE: Pivotal trial have shown that patients with multiple sclerosis (MS) receiving ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are limited. The aim of this study was to evaluate the preliminary safety profile and effectiveness of ocrelizumab treatment for multiple sclerosis (MS) in a real-world clinical setting. METHODS: We conducted a retrospective study including consecutive patients from nine public hospitals in south-eastern Spain who received ocrelizumab after it was approved. RESULTS: A total of 228 MS patients were included (144 with relapsing-remitting MS [RRMS], 25 secondary progressive MS [SPMS], and 59 primary progressive MS [PPMS]). Median follow-up period was 12 months (range, 1-32). No evidence of disease activity (NEDA) status at year 1 was achieved in 91.2% of the relapsing MS (RMS) population, while disability progression was detected in 37.5% of the PPMS patients (median follow-up period, 19 months). The most common adverse events reported were infusion-related reactions and infections, with the most common infections being urinary tract infections followed by upper respiratory infections and COVID-19. INTERPRETATION: The preliminary results in our real-world setting show that ocrelizumab presented excellent results in suppressing disease activity with a favorable and consistent safety profile.
OBJECTIVE: Pivotal trial have shown that patients with multiple sclerosis (MS) receiving ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are limited. The aim of this study was to evaluate the preliminary safety profile and effectiveness of ocrelizumab treatment for multiple sclerosis (MS) in a real-world clinical setting. METHODS: We conducted a retrospective study including consecutive patients from nine public hospitals in south-eastern Spain who received ocrelizumab after it was approved. RESULTS: A total of 228 MS patients were included (144 with relapsing-remitting MS [RRMS], 25 secondary progressive MS [SPMS], and 59 primary progressive MS [PPMS]). Median follow-up period was 12 months (range, 1-32). No evidence of disease activity (NEDA) status at year 1 was achieved in 91.2% of the relapsing MS (RMS) population, while disability progression was detected in 37.5% of the PPMS patients (median follow-up period, 19 months). The most common adverse events reported were infusion-related reactions and infections, with the most common infections being urinary tract infections followed by upper respiratory infections and COVID-19. INTERPRETATION: The preliminary results in our real-world setting show that ocrelizumab presented excellent results in suppressing disease activity with a favorable and consistent safety profile.
Authors: Ana Muñoz-Jurado; Begoña M Escribano; Eduardo Agüera; Javier Caballero-Villarraso; Alberto Galván; Isaac Túnez Journal: J Neurol Date: 2022-07-05 Impact factor: 6.682
Authors: Nabil Seery; Sifat Sharmin; Vivien Li; Ai-Lan Nguyen; Claire Meaton; Roberts Atvars; Nicola Taylor; Kelsey Tunnell; John Carey; Mark P Marriott; Katherine A Buzzard; Izanne Roos; Chris Dwyer; Josephine Baker; Lisa Taylor; Kymble Spriggs; Trevor J Kilpatrick; Tomas Kalincik; Mastura Monif Journal: CNS Drugs Date: 2021-04-13 Impact factor: 5.749
Authors: Roberta Lanzillo; Antonio Carotenuto; Elisabetta Signoriello; Rosa Iodice; Giuseppina Miele; Alvino Bisecco; Giorgia Teresa Maniscalco; Leonardo Sinisi; Felice Romano; Maria Di Gregorio; Luigi Lavorgna; Francesca Trojsi; Marcello Moccia; Mario Fratta; Nicola Capasso; Raffaele Dubbioso; Maria Petracca; Antonio Luca Spiezia; Antonio Gallo; Martina Petruzzo; Marcello De Angelis; Simona Bonavita; Giacomo Lus; Gioacchino Tedeschi; Vincenzo Brescia Morra Journal: J Clin Med Date: 2022-04-07 Impact factor: 4.964